Buying a Dry Needling Package on the Strength of One Pre-Post Study

This is a single-group pre-post design - low-level evidence (roughly level 4) that cannot establish cause and effect.

Threats:

• No control group. Natural recovery, regression to the mean, and the placebo/expectation effect are all live explanations for a 2-point pain drop in a fluctuating condition.
• Co-intervention. Every subject also received a balance program, which plausibly drives both the pain and the balance test gains. The design cannot separate the two.
• Detection bias. The treating therapist measured the outcomes unblinded, and knew the hypothesis.
• Attrition bias. Four of 32 dropped out (12.5%) and were excluded rather than analyzed as intention-to-treat, which typically inflates the observed effect.
• No follow-up. We cannot tell whether any benefit outlasted the last session.
• Small, single-site sample with no power calculation and no reporting of adverse events - important for a needling intervention.

Bottom line: the study shows that people improved while receiving this package. It does not show that dry needling caused the improvement or that it beats the balance program alone.

The 2.1-point drop sits near commonly cited thresholds for clinically important change in chronic musculoskeletal pain (about 2 points, or roughly 30%, on a 0-10 scale). But the threshold is only meaningful if the change is attributable and if we know the starting point:

• Going from 7 to 4.9 is a meaningful shift for a patient; going from 2.5 to 0.4 in a group whose primary problem is instability, not pain, may be noise.
• Chronic ankle instability is defined by giving-way and recurrent sprains, not by pain intensity. A pain scale is a weak primary outcome here; function, episodes of instability, and return to sport matter more.
• The balance improvement is confounded by the balance program, which is already known to work.
• Group means do not predict individual response. A mean change of 2.1 says nothing about the variance, and without a standard deviation or responder analysis you cannot tell whether most patients improved a little or a few improved a lot.

So: promising, plausible, unconfirmed. It justifies a cautious trial with measurement, not a 14,000-dollar capital purchase.

Tell the owner: this study cannot support a 14,000-dollar purchase plus training. It is uncontrolled, unblinded, and short-term. The honest recommendation is to defer purchase and, if there is interest, run a small internal trial with standardized outcomes, a blinded assessor, and adverse event tracking, or start with one trained clinician and a referral pathway.

What would change the recommendation: a randomized trial with a credible sham or an active comparator, blinded outcome assessment, intention-to-treat analysis, three- to six-month follow-up, and reported harms.

For that specific patient, safety and scope come before efficacy:

• Warfarin: needling creates bleeding risk. Coordinate with the prescriber, check the INR and timing of the dose, avoid deep or vascular structures, and get informed consent that names bleeding as a risk.
• Diabetes: higher infection risk and impaired healing; ensure glycemic control, use aseptic technique, inspect and consent for skin infection risk, and avoid needling compromised or insensate tissue.
• Neuropathy: reduced sensation means he cannot report a deep or misplaced needle accurately.
• Scope: confirm your state practice act, your credentialing, and clinic consent and adverse-event policies before the first treatment.

Efficacy is a question for the evidence; safety and licensure are questions for this patient, today.